Aumolertinib (trade name Ameile) is a pharmaceutical drug for the treatment of cancer. It is an

epidermal growth factor receptor The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor (biochemistry), receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligand (biochemistry ...

(EGFR)

tyrosine kinase inhibitor A tyrosine kinase inhibitor (TKI) is a pharmaceutical drug that inhibits tyrosine kinases. Tyrosine kinases are enzymes responsible for the activation of many proteins by signal transduction cascades. The proteins are activated by adding a phosph ...

(TKI). In China, aumolertinib is approved for the treatment of patients with EGFR T790M mutation—positive

non-small-cell lung cancer Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitiv ...

(NSCLC) who have progressed on or after other EGFR TKI therapy.

References

Tyrosine kinase inhibitors Indoles Aminopyrimidines Acrylamides Dimethylamino compounds Antineoplastic and immunomodulating drugs Methoxy compounds {{antineoplastic-drug-stub